TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Uveitis Steroid Treatment (MUST) Trial
Brief Summary: The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3
B: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
D: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
Brief Summary: The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group mediated cognitive behavioral (GMCB) sessions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions | Intervention Type: BEHAVIORAL; Name: Group mediated cognitive behavioral (GMCB) sessions; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Health education sessions; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control--Resistance Training | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Control--Resistance Training; Assigned to Arm(s): 3
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
Brief Summary: The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
B: Arm Label: Intervention group: Angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty | Arm Label: Control: Supervised Exercise Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised Exercise Therapy | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): Intervention group: Angioplasty | Intervention Type: OTHER; Name: Supervised Exercise Therapy; Assigned to Arm(s): Control: Supervised Exercise Therapy
C: Arm Label: INVASIVE (INV) group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: INVASIVE (INV) treatment, Other: Best medical treatment (BMT) | Arm Label: NON-INVASIVE (NON) group; Type: ACTIVE_COMPARATOR; Interventions: Other: Best medical treatment (BMT) | Intervention Type: PROCEDURE; Name: INVASIVE (INV) treatment; Assigned to Arm(s): INVASIVE (INV) group | Intervention Type: OTHER; Name: Best medical treatment (BMT); Assigned to Arm(s): INVASIVE (INV) group, NON-INVASIVE (NON) group
D: Arm Label: PTA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Supervised Exercise Programme (SEP) | Arm Label: PTA+SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Combined Treatment | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA | Intervention Type: PROCEDURE; Name: Supervised Exercise Programme (SEP); Assigned to Arm(s): SEP | Intervention Type: PROCEDURE; Name: Combined Treatment; Assigned to Arm(s): PTA+SEP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
Brief Summary: The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.


Options:
A: Arm Label: Best medical treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supervised exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised exercise training | Intervention Type: BEHAVIORAL; Name: Supervised exercise training; Assigned to Arm(s): Supervised exercise training
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control--Resistance Training | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Control--Resistance Training; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
Brief Summary: The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.


Options:
A: Arm Label: Heparin-bonded endoluminal fempop bypass; Type: EXPERIMENTAL; Interventions: Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass | Arm Label: Surgical femoro-popliteal bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical femoro-popliteal bypass. | Intervention Type: PROCEDURE; Name: Heparin-bonded ePTFE endoluminal fem-pop bypass; Assigned to Arm(s): Heparin-bonded endoluminal fempop bypass | Intervention Type: PROCEDURE; Name: Surgical femoro-popliteal bypass.; Assigned to Arm(s): Surgical femoro-popliteal bypass
B: Arm Label: Open Bypass Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Bypass Surgery | Arm Label: Angioplasty and Stenting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty and Stenting | Intervention Type: PROCEDURE; Name: Open Bypass Surgery; Assigned to Arm(s): Open Bypass Surgery | Intervention Type: PROCEDURE; Name: Angioplasty and Stenting; Assigned to Arm(s): Angioplasty and Stenting
C: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia
Brief Summary: Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.


Options:
A: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab
B: Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg
C: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia
Brief Summary: Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.


Options:
A: Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M
D: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination With Methotrexate for the Long-term Treatment of Crohn's Disease (CD)
Brief Summary: The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy.


Options:
A: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade
B: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
C: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Pilot Study of Pallidal Deep Brain Stimulation of Cervical Dystonia
Brief Summary: The purposes of this study are:

* to determine if bilateral pallidal deep brain stimulation results in improvement in neck postures/movements;
* to determine if bilateral pallidal deep brain stimulation results in improvement in quality of life; and
* to document the adverse effects of surgery in patients with cervical dystonia.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Bilateral Deep Brain Stimulation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: best medical therapy | Intervention Type: DEVICE; Name: Bilateral Deep Brain Stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: best medical therapy; Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Deep brain stimulation; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Deep brain stimulation of the internal globus pallidus; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Intervention Type: DEVICE; Name: Deep brain stimulation (DBS); Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine whether the addition of omalizumab in patients with poorly controlled asthma (because of poor adherence) will decrease allergic airway inflammation and improve asthma control.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg
B: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab
C: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
D: Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine whether the addition of omalizumab in patients with poorly controlled asthma (because of poor adherence) will decrease allergic airway inflammation and improve asthma control.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A, B, C
B: Intervention Type: DRUG; Name: SB-240563 (Mepolizumab); Assigned to Arm(s): N/A
C: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)
D: Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease
Brief Summary: The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control

Answer: B